Efficacia del ginkgo biloba (Brenstar®) nel trattamento degli acufeni e delle vertigini
Keywords:
Ginkgo Biloba, Brenstar©, Acufeni, Vertigini, Tinnitus, DizzinessAbstract
Nello studio, realizzato presso l’U.O. ORL di Castel San Pietro Terme (Bologna), è stato utilizzato un prodotto a base di Gingko Biloba associata a Vitis Vinifera, Camelia Sinensis, Fosfatidilserina, L-Acetilcarnitina, Acido Folico e Magnesio (BRENSTAR©) per il trattamento di pazienti affetti da acufeni e vertigini. I 30 pazienti reclutati sono stati trattati per tre mesi alla posologia di un flaconcino al giorno. Prima dell’inizio della terapia tutti i pazienti hanno effettuato esame audiometrico e ABR e compilato i relativi questionari. Nei pazienti trattati è stato riscontrato un miglioramento della sintomatologia e della qualità di vita.Effectiveness of ginkgo biloba (Brenstar©) in the treatment of tinnitus and vertigo
In the study, conducted at the U. O. ORL Castel San Pietro Terme (Bologna), was used a product based on Gingko Biloba associated with Vitis vinifera, Camelia Sinensis, Phosphatidylserine, L-Acetylcarnitine, folic acid and magnesium (BRENSTAR©) for the treatment of patients suffering from tinnitus and dizziness. The 30 enrolled patients were treated for three months at a dose of one vial a day. Before initiation of therapy all patients underwent audiometry and ABR and completed the relevant questionnaires. Treated patients has been reported an improvement in symptoms and quality of life.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.